Cerus Corporation (Nasdaq: CERS) to Ring the Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center...
April 07 2017 - 10:57AM
What:Cerus Corporation (Nasdaq:CERS), a
biomedical products company focused in the field of blood
transfusion safety, will visit the Nasdaq Entrepreneurial Center in
San Francisco.
In honor of the occasion, William ‘Obi’ M. Greenman,
President & Chief Executive Officer, will ring the
Closing Bell.
Where:Nasdaq Entrepreneurial Center – 505
Howard Street, San Francisco, CA
When:Monday, April 10, 2017 – 3:45 p.m. to 4:00
p.m. ET / 12:45 p.m. to 1:00 p.m. PT
Cerus Contact:Lainie Corten - Vice President,
Global Marketing & Investor Relations(925)
288-6137ir@cerus.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About CerusCerus Corporation is a
biomedical products company focused in the field of blood
transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by
inactivating a broad range of pathogens such as viruses, bacteria
and parasites that may be present in donated blood. The nucleic
acid targeting mechanism of action of the INTERCEPT treatment is
designed to inactivate established transfusion threats, such as
hepatitis B and C, HIV, West Nile virus and bacteria, as well as
emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT
Blood System for both platelets and plasma in the United
States, Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions
around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com for
information about Cerus.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables clients
to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 85 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
approximately 3,800 listed companies with a market value of $10.1
trillion and nearly 18,000 corporate clients. To learn more, visit:
business.nasdaq.com.
-NDAQA-
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024